Regulation of cAMP phosphodiesterase mRNAs expression in rat brain by acute and chronic fluoxetine treatment. An in situ hybridization study

Neuropharmacology

Volumn 43, Issue 7, 2002, Pages 1148-1157

  Miró, Xavier ^a   Pérez Torres, Silvia ^b   Artigas, Francesc ^b   Puigdomènech, Pere ^a   Palacios, José M ^b,c   Mengod, Guadalupe ^b  

^a INSTITUT DE BIOLOGIA MOLECULAR DE BARCELONA   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c Almirall Prodesfarma ^*  (Spain)

Author keywords

Antidepressants; BDNF; Fluoxetine; In situ hybridization; PDE4; PDE4D splice variants; Rolipram

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLIC AMP PHOSPHODIESTERASE; FLUOXETINE; ISOENZYME; MESSENGER RNA; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; ROLIPRAM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING SITE; BRAIN REGION; CONTROLLED STUDY; DOWN REGULATION; DRUG BINDING; DRUG EFFECT; ENZYME SUBUNIT; GENETIC CODE; IN SITU HYBRIDIZATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; RAT; RNA SPLICING; RNA TRANSCRIPTION;

EID: 0036913698     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(02)00220-4     Document Type: Article

References (43)

1. Andrade R., Malenka R.C., Nicoll R.A. A G protein couples serotonin and GABAB receptors to the same channels in hippocampus. Science. 234:1986;1261-1265.
2. 3H]cAMP binding to cytosolic and particulate protein kinase A in post-mortem brain staged for Alzheimer's disease neurofibrillary changes and amyloid deposits. Brain Research. 818:1999;383-396.
3. Capece M.L., Lydic R. cAMP and protein kinase A modulate cholinergic rapid eye movement sleep generation. American Journal of Physiology. 273:1997;R1430-R1440.
4. Conti M., Jin S.L. The molecular biology of cyclic nucleotide phosphodiesterases. Progress in Nucleic Acid Research and Molecular Biology. 63:1999;1-38.
5. Cowburn R.F., Fowler C.J., O'Neill C. Neurotransmitters, signal transduction and second-messengers in Alzheimer's disease. Acta Neurologica Scandinavica. 165:(Suppl):1996;25-32.
6. De Vivo M., Maayani S. Characterization of the 5-hydroxytryptamine 1a receptor-mediated inhibition of forskolin-stimulated adenylate cyclase activity in guinea pig and rat hippocampal membranes. Journal of Pharmacology and Experimental Therapeutics. 238:1986;248-253.
7. Duman R.S., Heninger G.R., Nestler E.J. A molecular and cellular theory of depression. Archives of General Psychiatry. 54:1997;597-606.
8. Fisher D.A., Smith J.F., Pillar J.S., St Denis S.H., Cheng J.B. Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase. Biochemical and Biophysical Research Communications. 246:1998;570-577.
9. Fleischhacker W.W., Hinterhuber H., Bauer H., Pflug B., Berner P., Simhandl C., Wolf R., Gerlach W., Jaklitsch H., Sastre-y-Hernandez M. A multicenter double-blind study of three different doses of the new cAMP-phosphodiesterase inhibitor rolipram in patients with major depressive disorder. Neuropsychobiology. 26:1992;59-64.
10. Fujimaki K., Morinobu S., Duman R.S. Administration of a cAMP phosphodiesterase 4 inhibitor enhances antidepressant-induction of BDNF mRNA in rat hippocampus. Neuropsychopharmacology. 22:2000;42-51.
11. Genain C.P., Roberts T., Davis R.L., Nguyen M.H., Uccelli A., Faulds D., Li Y., Hedgpeth J., Hauser S.L. Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Proceedings of the National Academy of Sciences of the USA. 92:1995;3601-3605.
12. Haddjeri N., Blier P., de Montigny C. Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors. Journal of Neuroscience. 18:1998;10150-10156.
13. Hayashi M., Matsushima K., Ohashi H., Tsunoda H., Murase S., Kawarada Y., Tanaka T. Molecular cloning and characterization of human PDE8B, a novel thyroid- specific isozyme of 3′,5′-cyclic nucleotide phosphodiesterase. Biochemical and Biophysical Research Communications. 250:1998;751-756.
14. Hervas I., Vilaro M.T., Romero L., Scorza M.C., Mengod G., Artigas F. Desensitization of 5-HT(1A) autoreceptors by a low chronic fluoxetine dose effect of the concurrent administration of WAY-100635. Neuropsychopharmacology. 24:2001;11-20.
15. Hofer M., Paglius S.R., Hohn A., Leibrock J., Barde Y.A. Regional distribution of brain-derived neurotrophic factor mRNA in the adult mouse brain. EMBO Journal. 9:1990;2459-2464.
16. Houslay M.D. Adaptation in cyclic AMP signalling processes: a central role for cyclic AMP phosphodiesterases. Seminal Cell Development and Biology. 9:1998;161-167.
17. Houslay M.D. PDE4 cAMP-specific phosphodiesterases. Progress in Nucleic Acid Research and Molecular Biology. 69:2001;249-315.
18. Hulley P., Hartikka J., Abdel'Al S., Engels P., Buerk H.R., Wiederhold K.H., Muller T., Kelly P., Lowe D., Lubbert H. Inhibitors of type IV phosphodiesterases reduce the toxicity of MPTP in substantia nigra neurons in vivo. European Journal of Neuroscience. 7:1995;2431-2440.
19. Jones B.E. Paradoxical sleep and its chemical/structural substrates in the brain. Neuroscience. 40:1991;637-656.
20. Kato H., Araki T., Itoyama Y., Kogure K. Rolipram, a cyclic AMP-selective phosphodiesterase inhibitor, reduces neuronal damage following cerebral ischemia in the gerbil. European Journal of Pharmacology. 272:1995;107-110.
21. 3H]rolipram. Brain Research. 503:1989;229-245.
22. McGeer P.L., McGeer E.G. The inflammatory response system of brain: implications for therapy of Alzheimer's and other neurodegenerative diseases. Brain Research and Brain Research Reviews. 21:1995;195-218.
23. Menkes D.B., Rasenick M.M., Wheeler M.A., Bitensky M.W. Guanosine triphosphate activation of brain adenylate cyclase: enhancement by long-term antidepressant treatment. Science. 219:1983;65-67.
24. Miro X., Perez-Torres S., Puigdomenech P., Palacios J.M., Mengod G. Differential distribution of PDE4D splice variant mRNAs in rat brain suggests association with specific pathways and presynaptical localization. Synapse. 45:2002;259-269.
25. Nestler E.J., Terwilliger R.Z., Duman R.S. Chronic antidepressant administration alters the subcellular distribution of cyclic AMP-dependent protein kinase in rat frontal cortex. Journal of Neurochemistry. 53:1989;1644-1647.
26. Nibuya M., Morinobu S., Duman R.S. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. Journal of Neuroscience. 15:1995;7539-7547.
27. Nibuya M., Nestler E.J., Duman R.S. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. Journal of Neuroscience. 16:1996;2365-2372.
28. O'Donnell J.M., Frith S. Behavioral effects of family-selective inhibitors of cyclic nucleotide phosphodiesterases. Pharmacology, Biochemistry and Behaviour. 63:1999;185-192.
29. 3H]rolipram binding autoradiography. Comparison with monkey and rat brain. Journal of Chemical Neuroanatomy. 20:2000;349-374.
30. Pompeiano M., Palacios J.M., Mengod G. Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: correlation with receptor binding. Journal of Neuroscience. 12:1992;440-453.
31. Rocamora N., Palacios J.M., Mengod G. Limbic seizures induce a differential regulation of the expression of nerve growth factor, brain-derived neurotrophic factor and neurotrophin-3, in the rat hippocampus. Brain Research and Molecular Brain Research. 13:1992;27-33.
32. Schwaninger M., Schofl C., Blume R., Rossig L., Knepel W. Inhibition by antidepressant drugs of cyclic AMP response element- binding protein/cyclic AMP response element-directed gene transcription. Molecular Pharmacology. 47:1995;1112-1118.
33. Sharpley A.L., Cowen P.J. Effect of pharmacologic treatments on the sleep of depressed patients. Biology of Psychiatry. 37:1995;85-98.
34. Sheng M., Greenberg M.E. The regulation and function of c-fos and other immediate early genes in the nervous system. Neuron. 4:1990;477-485.
35. Siuciak J.A., Lewis D.R., Wiegand S.J., Lindsay R.M. Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacology, Biochemistry and Behaviour. 56:1997;131-137.
36. Soderling S.H., Beavo J.A. Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Current Opinion in Cell Biology. 12:2000;174-179.
37. Suda S., Nibuya M., Ishiguro T., Suda H. Transcriptional and translational regulation of phosphodiesterase type IV isozymes in rat brain by electroconvulsive seizure and antidepressant drug treatment. Journal of Neurochemistry. 71:1998;1554-1563.
38. Swinnen J.V., Joseph D.R., Conti M. The mRNA encoding a high-affinity cAMP phosphodiesterase is regulated by hormones and cAMP. Proceedings of the National Academy of Sciences of the USA. 86:1989;8197-8201.
39. Takahashi M., Terwilliger R., Lane C., Mezes P.S., Conti M., Duman R.S. Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms. Journal of Neuroscience. 19:1999;610-618.
40. Timmusk T., Palm K., Metsis M., Reintam T., Paalme V., Saarma M., Persson H. Multiple promoters direct tissue-specific expression of the rat BDNF gene. Neuron. 10:1993;475-489.
41. Wachtel H. Potential antidepressant activity of rolipram and other selective cyclic adenosine 3′,5′-monophosphate phosphodiesterase inhibitors. Neuropharmacology. 22:1983;267-272.
42. Ye Y., Jackson K., O'Donnell J.M. Effects of repeated antidepressant treatment of type 4A phosphodiesterase (PDE4A) in rat brain. Journal of Neurochemistry. 74:2000;1257-1262.
43. Zajecka J.M. Clinical issues in long-term treatment with antidepressants. Journal of Clinical Psychiatry. 61:(Suppl 2):2000;20-25.